These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 9667966

  • 21. Interactions of cryptolepine and neocryptolepine with unusual DNA structures.
    Guittat L, Alberti P, Rosu F, Van Miert S, Thetiot E, Pieters L, Gabelica V, De Pauw E, Ottaviani A, Riou JF, Mergny JL.
    Biochimie; 2003 May; 85(5):535-47. PubMed ID: 12763313
    [Abstract] [Full Text] [Related]

  • 22. [Synthesis and biological activity of a series of benzopyran derivatives].
    Tang L, Yang YS, Ji RY.
    Yao Xue Xue Bao; 2008 Feb; 43(2):162-8. PubMed ID: 18507343
    [Abstract] [Full Text] [Related]

  • 23. Recent Advances in the Chemistry and Pharmacology of Cryptolepine.
    Shnyder SD, Wright CW.
    Prog Chem Org Nat Prod; 2021 Feb; 115():177-203. PubMed ID: 33797643
    [Abstract] [Full Text] [Related]

  • 24. Metabolism of cryptolepine and 2-fluorocryptolepine by aldehyde oxidase.
    Stell JG, Wheelhouse RT, Wright CW.
    J Pharm Pharmacol; 2012 Feb; 64(2):237-43. PubMed ID: 22221099
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
    Crane L, Anastassiadou M, El Hage S, Stigliani JL, Baziard-Mouysset G, Payard M, Leger JM, Bizot-Espiard JG, Ktorza A, Caignard DH, Renard P.
    Bioorg Med Chem; 2006 Nov 15; 14(22):7419-33. PubMed ID: 16889967
    [Abstract] [Full Text] [Related]

  • 29. Synthesis and properties of oligonucleotides carrying cryptolepine derivatives.
    Eritja R.
    Chem Biodivers; 2004 Feb 15; 1(2):289-95. PubMed ID: 17191847
    [Abstract] [Full Text] [Related]

  • 30. Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
    Kumar A, Sharma S, Tripathi VD, Maurya RA, Srivastava SP, Bhatia G, Tamrakar AK, Srivastava AK.
    Bioorg Med Chem; 2010 Jun 01; 18(11):4138-48. PubMed ID: 20471838
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and in vivo antihyperglycemic activity of nature-mimicking furanyl-2-pyranones in STZ-S model.
    Singh FV, Chaurasia S, Joshi MD, Srivastava AK, Goel A.
    Bioorg Med Chem Lett; 2007 May 01; 17(9):2425-9. PubMed ID: 17336063
    [Abstract] [Full Text] [Related]

  • 32. Studies on cryptolepine. III: Effect of cryptolepine on the tone and prostaglandin production in isolated rabbit duodenum.
    Noamesi BK, Bamgbose SO.
    Planta Med; 1984 Feb 01; 50(1):98-101. PubMed ID: 6739580
    [No Abstract] [Full Text] [Related]

  • 33. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM.
    J Med Chem; 1998 Dec 03; 41(25):5020-36. PubMed ID: 9836620
    [Abstract] [Full Text] [Related]

  • 34. Unravelling the pharmacological properties of cryptolepine and its derivatives: a mini-review insight.
    Tudu CK, Bandyopadhyay A, Kumar M, Radha, Das T, Nandy S, Ghorai M, Gopalakrishnan AV, Proćków J, Dey A.
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb 03; 396(2):229-238. PubMed ID: 36251044
    [Abstract] [Full Text] [Related]

  • 35. Studies on cryptolepine. II: Inhibition of carrageenan induced oedema by cryptolepine.
    Bamgbose SO, Noamesi BK.
    Planta Med; 1981 Apr 03; 41(4):392-6. PubMed ID: 7255566
    [No Abstract] [Full Text] [Related]

  • 36. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats.
    Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT.
    J Nat Prod; 2003 Jun 03; 66(6):788-92. PubMed ID: 12828463
    [Abstract] [Full Text] [Related]

  • 37. Synthesis and antihyperglycemic activity of 2-(substituted phenyl)-3-{[4-(1-naphthyl)-1,3-thiazol-2-yl] amino}-4-oxo-1,3-thiazolidin-5-ylacetic acid derivatives.
    Imran M, Yar MS, Khan SA.
    Acta Pol Pharm; 2009 Jun 03; 66(1):51-6. PubMed ID: 19226969
    [Abstract] [Full Text] [Related]

  • 38. Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents.
    Yang B, Mei Y, Wang X, Deng X, Qian H, Huang W.
    Eur J Med Chem; 2014 Feb 12; 73():105-11. PubMed ID: 24384551
    [Abstract] [Full Text] [Related]

  • 39. Substituted indoloquinolines as new antifungal agents.
    Ablordeppey SY, Fan P, Li S, Clark AM, Hufford CD.
    Bioorg Med Chem; 2002 May 12; 10(5):1337-46. PubMed ID: 11886797
    [Abstract] [Full Text] [Related]

  • 40. Antihyperglycemic effects of newly synthesized 6,7-bis[2-(substitutedphenyl)-4-oxothiazolidin3yl1 quinoxaline 2,3-(1 FH, 4 H)-diones.
    Pawar PY, Bhise SB.
    Indian J Physiol Pharmacol; 2006 May 12; 50(4):431-4. PubMed ID: 17402276
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.